logo
logo

Kytopen Raises $30M In Series A Funding, Led By Northpond Ventures, To Transform Non-Viral Delivery Via The Flowfect Platform

Sep 28, 2021•almost 4 years ago

Amount Raised

$30 Million

Round Type

series a

Cambridge

Description

Kytopen Corp., a biotechnology company spun out of MIT offering a scalable technology for engineered cell therapies, today announced it has raised $30 million in an oversubscribed Series A funding. The new capital will be used to commercialize Kytopen’s Flowfect® Tx for cGMP-compliant cell therapy manufacturing and move towards treating the first human patient with Flowfect® engineered cells. Kytopen’s mission is to enable simple and efficient non-viral manufacturing of cell therapies in days versus weeks to increase patient access to life-saving therapies.

Company Information

Company

Kytopen

Location

Cambridge, Maryland, United States

About

Kytopen, a spin-out of Prof. Cullen Buie’s lab at MIT, is a transformative biotechnology company that offers a customizable yet scalable multi-solution platform, which seamlessly links the discovery, development, and manufacturing phases of cell engineering. Flowfect®, a gentle, non-viral delivery method unlocks new therapeutic approaches, by engineering immune cells with minimal disruption, preserving the functionality and viability of human cells and enhancing the cell’s biology. The Flowfect® platform accelerates therapies from the bench to the clinic through flexibility and scalability, which drives higher cell yields, faster approvals, and better outcomes from potentially curative cell-based treatments. For more information, visit: www.kytopen.com

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech